MDS Center

iPhone / Medecine

MDS Center: Your Comprehensive Guide to Managing Myelodysplastic Syndromes

The MDS Center app is designed specifically for physicians who treat myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Developed by MDS experts under the guidance of the European Myelodysplastic Syndromes Cooperative Group (EMSCO), this comprehensive app provides a range of valuable tools to assist physicians in making informed decisions and optimizing patient care.

Navigate seamlessly through the latest MDS and CMML treatment guidelines with our interactive therapy algorithm. Step by step, the app guides you through the appropriate therapeutic approach based on the patient's individual characteristics and clinical context.

Leverage our user-friendly study finder to locate current clinical trials related to MDS and CMML in Germany, Austria, and Switzerland. Quickly filter your search based on specific criteria such as diagnosis, phase, symptoms, therapy line, or study center location. Access detailed descriptions, contact information, and participant eligibility criteria for each study.

Accurately classify MDS and CMML using our interactive calculator for the WHO classifications of 2016 and 2008. Compare your calculations with comprehensive overviews for reference. Additionally, determine patient prognosis with our calculators for the IPSS, IPSS-R, and CPSS-Mol, ensuring informed decision-making regarding patient care.

Keep up-to-date with the latest developments in the MDS and CMML field by accessing news updates from our MDS network. Stay informed about research breakthroughs, clinical guidelines, and emerging therapies.

Developed by physicians for physicians, the MDS Center app is your trusted companion in the complex world of MDS and CMML management. Leverage its comprehensive suite of tools to enhance patient care and contribute to optimal outcomes.

Quoi de neuf dans la dernière version ?

Version 1.5 features a visual re-design of the user interface along with the following additions:

- integration of a classification tool for the WHO 2022 criteria
- overview on the IMWG 2023 response criteria
- updates to the treatment recommendations based on the latest verison of the Onkopedia guideline
- several minor improvements